Cholinergic abnormalities in Alzheimer's disease: identification of novel therapeutic targets [ 2004 - 2006 ]

Research Grant

Researchers: Prof David Small (Principal investigator) ,  Prof Marie-Isabel Aguilar ,  Prof Mary Collins Chebib

Brief description The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase and 2) nicotinic receptors, which are known to be important for memory. The aim of this application is to identify the mechanisms by which amyloid protein targets acetylcholinesterase and nicotinic receptors and to design inhibitors of this interaction which may ultimately provide a platform for future drug development.

Funding Amount $AUD 478,500.00

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant